Clinical Trials List
2022-07-01 - 2028-01-24
Phase I
Recruiting3
ICD-10C16.9
Malignant neoplasm of stomach, unspecified
ICD-10C7A.092
Malignant carcinoid tumor of the stomach
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9151.9
Malignant neoplasm of stomach, unspecified
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 方文良 Division of General Surgery
- Ta-Chung Chao Division of Hematology & Oncology
- Chien-An Liu Division of Radiology
- San-Chi Chen Division of Hematology & Oncology
- 林泰祺 Division of Ophthalmology
- 黃國宏 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hui-Ching Wang Division of Hematology & Oncology
- 蔡祥麟 Division of Colorectal Surgery
- 高育青 Division of Hematology & Oncology
- Tsung-Jang Yeh Division of Hematology & Oncology
- Chieh-Han Chuang Division of General Surgery
- Jaw-Yuan Wang Division of Colorectal Surgery
- Jeng-Shiun Du Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wen-Chi Chou Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
- Tai-Sen Yeh Division of General Surgery
- Hung-Chih Hsu Division of Hematology & Oncology
- Ming-Mo Hou Division of Hematology & Oncology
- Tsai-Sheng Yang Division of Hematology & Oncology
- Chun-Nan Yeh Division of General Surgery
- 吳教恩 Division of Hematology & Oncology
- 張境夫 Division of Hematology & Oncology
- 徐潤德 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
60 participants
